Female Orgasmic Disorder (FOD)- Compounding Pharmacy Options
Female Orgasmic Disorder (FOD) is a disorder affecting 28% of women in the United States. FOD refers to difficulty reach orgasm. Women with FOD may take longer to have an orgasm, or she might not reach orgasm at all. FOD can cause significant distress to women and often times leads to other mental health and relationship issues if not addressed with a healthcare provider.
How is female orgasmic disorder (FOD) treated?
Treating female orgasmic disorder often depends on the cause, if it can be pinpointed. For example, if a woman is having problems reaching orgasm because of illness or medication, targeting those factors can certainly help.
Counseling or sex therapies are common treatment routes. Therapy can help a woman work through anxiety, depression, relationship problems, or past abuse.
Since there are no commercially available treatment options for FOD, many doctors have turned to Pavilion Compounding Pharmacy for our expertise solutions for FOD. Pavilion Compounding Pharmacy’s clinical pharmacists have researched and formulated novel products where the individual ingredients and routes of administration may help women increase the quality of their sexual lives. Many providers and patients have entrusted Pavilion Compounding Pharmacy to formulate a unique alternative treatment for FOD using Testosterone Intranasal spray.
Testosterone – The “Orgasm” hormone
Testosterone in women plays a vital role in the maintenance of the female genital system, including the labia majora, clitoris, and nipples. Low testosterone in women is associated with decreased activity in the portion of the brain that is responsible for emotion regulation, identification of the emotional significance of stimuli, and generation of an affective response. The presence of testosterone in women may be the single most important determinant of sexual readiness and mood, and has been positively linked to orgasm in many studies.
Testosterone Intranasal Spray in Clinical Research
In a Phase II clinical trial by Laan, et al, intranasal testosterone was studied for female orgasmic disorder (FOD) in 59 patients. Of the patients diagnosed with FOD and treated with intranasal testosterone, 40% of the treatment group reported experiencing an orgasm or sensations indicative of an orgasm for the first time. Women treated with intranasal testosterone also reported more intense feelings of sexual arousal after stimulation and showed an increased genital response.1
In another study by van Gorsel, et al, patients treated with intranasal testosterone had significantly higher vaginal pulse amplitude (VPA) responses as soon as 30 minutes following administration in FOD patients. VPA measures the pressure change of the blood vessels within the vagina, which indicate a sexual response.2
Can’t I use my Testosterone Cream?
When comparing the intranasal route to the intravenous route for testosterone application, Banks, et al, found that even though both routes deliver testosterone throughout the whole body, intranasal testosterone reaches concentrations in the brain at levels almost twice as high as the Intravenous (IV) route.3 Since the goal of this therapy is to activate central sexual mechanisms in the brain, applying testosterone as a cream may not give you the same effects as an intranasal spray.
How Do I Get Testosterone Intranasal Spray?
Pavilion Compounding Pharmacy’s compounded Intranasal Testosterone solution is available to patients by obtaining a prescription from your doctor. Call Pavilion Compounding Pharmacy today at 404-350-5780 to speak to one of our pharmacists about Intranasal Testosterone therapy. We may be able to request a prescription for Intranasal Testosterone from your doctor or refer you to one of the experts we work with. You can also contact us through our website, online chat, or e-mail us at email@example.com
Testosterone intranasal spray may be compounded as a 0.6mg/spray in a 5ml nasal spray bottle. Other concentrations and doses are available. A commonly prescribed dose based on the research is 1-3 sprays in nostril once daily 2-8 hours before planned sexual event
1.Laan E, Nievaart M, Tkachenko NM, Dickstein J, Kreppner W, Lunsen RHW. Randomized, placebo controlled, five-arm parallel group study to assess efficacy of TBS-2 intranasal gel using vibrotactile stimulation combined with visual sexual stimulation in women with anorgasmia. J Sex Med. 2013;10:165–166.
2. Gorsel H, Laan, Tkachenko NM, Dickstein J, Kreppner W. Pharmacokinetics and pharmacodynamic efficacy of testosterone intranasal gel in women with hypoactive sexual desire disorder and anorgasmia. J Sex Med. 2012;9(3):162–180.
3. Banks WA, Morley JE, Niehoff ML, Mattern C. Delivery of testosterone to the brain by intranasal administration: comparison to intravenous testosterone. J Drug Target. 2009;17(2):91-97.